The pharmaceutical industry has eagerly awaited the finalisation and publication of Annex 1 of the EU GMP Guidelines, which was released in August 2022. This document has become an internationally accepted regulatory standard, and its impact is profound. Annex 1 sets overarching principles for the design, operation, and control of facilities, equipment, systems, and procedures used in the manufacture of sterile medicinal products. It emphasises the importance of a consistent requirement for a Cleanroom Classification System (CCS) and the systematic application of Quality Risk Management (QRM).
Annex 1 explicitly acknowledges the development of isolator technology over the past two decades as a proven method for both sterile manufacturing and quality control. It recommends the use of barrier technologies, such as isolators, to enhance product protection against contamination risks from endotoxins, pyrogens, particles, and microorganisms introduced by personnel, materials, or the environment. Preventing operator involvement in critical aseptic steps is crucial, and Annex 1 identifies barrier systems as the preferred solution, requiring a scientific justification for any alternative environmental concepts.
The guideline's Section 2.1 emphasises the need for special requirements in the manufacture of sterile products to minimise microbial, particulate, and endotoxin/pyrogen contamination. It suggests the use of appropriate technologies, such as Restricted Access Barrier Systems (RABS) and isolators, to protect products from extraneous sources of contamination and facilitate rapid detection of potential contaminants. Section 8.9 further reinforces the use of RABS and isolators to reduce the need for critical interventions and minimise contamination risks.
Section 4.3 explicitly states that RABS or isolators are beneficial in assuring required conditions and minimising microbial contamination associated with direct human interventions in the critical zone. Their use should be considered in the CCS, and any alternative approaches must be justified. This endorsement of barrier technology, characterised by an aseptic background environment, physical separation of product handling from contamination sources, automated decontamination processes, unidirectional airflow, and defined pressure differentials, is a significant development.
Isolators, in particular, stand out for their fully closed and rigid physical separation between the surrounding environment and the aseptic processing area. This design enables a higher Sterility Assurance Level (SAL) compared to RABS-based solutions, making isolators the highest standard for aseptic processing from a drug safety perspective. Figure 1 visually compares various environmental concepts and their associated SAL values.
Annex 1 also highlights the consideration of robotic solutions in Sections 2.1 and 8.9, reflecting the goal of minimising direct human intervention in aseptic processes. Robotic systems, such as gloveless isolator filling systems, offer the highest levels of safety, operational flexibility, and efficiency. These systems enable the full automation of critical aseptic operations, further enhancing drug safety and quality.
The CCS, a central element of Annex 1, directly influences isolators designed for aseptic applications. A risk-based assessment of the isolator system design, including installation and integration, is essential at an early stage. This assessment ensures effective cleaning, prevents particulate or microbiological contamination of sterile products, and avoids cross-contamination, especially in multi-product operations. The design also plays a crucial role in surface decontamination using H₂O₂ and the implementation of robotic solutions to minimise manual interventions within the aseptic zone.
In conclusion, Annex 1 of the GMP guidelines has significantly strengthened the role of isolator technology, positioning it as the most appropriate background environment for drug and patient safety. The guideline explicitly advocates for the use of isolators, requiring a formal justification when an alternative background environment is chosen. This endorsement solidifies isolators' position as the highest level of environmental protection for aseptically manufactured sterile pharmaceutical products, ensuring the highest standards of safety and quality in the pharmaceutical industry.
